Author:
Ciesek Sandra,Manns Michael P.
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Hepatology
Reference9 articles.
1. Manns, M. P. et al. The way forward in HCV treatment—finding the right path. Nat. Rev. Drug Discov. 6, 991–1000 (2007).
2. McHutchison, J. G. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292–1303 (2010).
3. Kwo, P. Y. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705–716 (2010).
4. Jacobson, I. M. et al. Telaprevir in combination with Peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study [abstract 211]. Hepatology 52 (Suppl.), 427A (2010).
5. Poordad, F. et al. Boceprevir (BOC) combined with Peginterferon alfa-2B/ribavirin for treatment-naive patients with hepatitis C virus (HCV) genotype 1 SPRINT-2 final results. Hepatology 52 (Suppl.), 107A (2010).
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献